期刊文献+

尿激酶型纤溶酶原激活物的表达与慢性重型肝炎预后的相关性 被引量:2

Relationship between the prognosis of chronic severe hepatitis and the expression of urokinase-type plasminogen activator
在线阅读 下载PDF
导出
摘要 探讨尿激酶型纤溶酶原激活物(Urokinase-type plasminogen activator,UPA)的表达与慢性重型肝炎的预后关系。我们对23例慢性重型肝炎患者采用Child-Pugh分级方法进行肝功能分级,并按存活与死亡分为存活组和死亡组。用酶联免疫吸附测定法(ELISA法)测定UPA。结果①慢性重型肝炎患者年龄小于50岁的UPA值(0.83±0.16)ng/ml,大于或等于50岁的UPA值(0.96±0.31)ng/ml,两组比较t=1.341,P>0.05;②a存活组UPA值(0.43±0.25)ng/ml,b死亡组UPA值(0.97±0.38)ng/ml,两组比较t=3.883,P<0.001。说明慢性重型肝炎患者的UPA表达与其年龄无关,而与其预后密切相关。 To study the relationship between the prognosis of chronic severe hepatitis and the expression of urokinase-type plasminogen activator(UPA).The liver functions of 23 cases with chronic severe hepatitis were classified according to Child-pugh.And these cases were divided into two groups,live group and death group.The level of UPA in the two groups was analyzed with ELISA.The results showed that there was not significantly different between the level of UPA in the cases over 50 age(0.83±0.16ng/ml) and in the cases below 50 age(0.96±0.31ng/ml) (t=1.341,P>0.05).It also showed that the level of UPA in live group(0.43±0.25ng/ml)was significantly lower than that in death group(0.97±0.38ng/ml)(t=3.883,P<0.01).It can be concluded that the UPA expression was closely related to the prognosis of chronic severe hepatitis,but not to age.
出处 《临床肝胆病杂志》 CAS 2007年第3期170-171,共2页 Journal of Clinical Hepatology
基金 广西科学基金资助项目(桂科基0342033 桂科基0143059)
关键词 尿激酶型纤溶酶原激活物 慢性重型肝炎 肝纤维样变 肝细胞坏死 肝小叶改建 urokinase-type plasminogen activator chronic severe hepatitis hepatofibrosis hepatic cell necrosis hepatic lobules change
  • 相关文献

参考文献5

  • 1叶一农,柯伟民.重型肝炎预后影响指标的研究概况[J].临床肝胆病杂志,2005,21(3):184-187. 被引量:1
  • 2[2]Kienast J,Padr T.Expression of Urokinase-type plasminogen aetivator in atheroselerotic coronary arteries from human heart explants[J].Zhromb H aemost,1998,79:579-586.
  • 3[3]Chavakis T,Kanse SM,Yutzy B,et al.Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor:urokinase complexes[J].Blood,1998,91:2305-2312.
  • 4[4]Pyke C,Kristenscn P,Ralfkiser E,et al.Urokinase-type plasminogen activator is expressed in stmmal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas[J].Am J Biol Chem,1996,271:22885.
  • 5李德旭,杨镇,邱新光,吴小勇,李海洋.猪胆汁性肝纤维化的形成机制研究[J].中华实验外科杂志,2003,20(1):16-17. 被引量:9

二级参考文献39

  • 1周子文,刘沛,王兆荃,董祥家,吕先科.重症肝炎末梢血T细胞亚群分布的研究[J].中国医科大学学报,1993,22(4):292-293. 被引量:1
  • 2张国安,刘小朋,陈志群,郑英,陈紫榕.病毒性肝炎患者白细胞介素-6的检测及其临床意义[J].标记免疫分析与临床,1995,2(1):12-14. 被引量:4
  • 3Fujiwara K, Mochida S. Indications and criteria for liver transplantation for fulminant hepatic failure [ J ]. J Gastroenterol, 2002,37 Suppl 113: 74 -77.
  • 4Omata M, Ehata T, Yokosuka O, et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis[J].N Engl J Med, 1991,324(24): 1699- 1704.
  • 5Liang TJ, Hasegawa K, Munoz S J, et al. Hepatitis B virus precore mutation and fulminant hepatitis in the United States[J]. J Clin Invest, 1994,93(2) :550 - 555.
  • 6Murray - Lyon IM, Orr AH, Gazzard B, et al. Prognostic value of serum alpha- fetoprotein in fulminant hepatic failure including patients treated by charcoal haemoperfusion[ J]. Gut, 1976,17(8) :576 - 580.
  • 7Fiaccadori F, Pedretti G, Ferrari C, et al. Insulin and glucagon levels in fulminant hepatic failure in man[J]. Dig Dis Sci. 1991,36(6) :801 -808.
  • 8John G,O'Grady, Graeme J, et al. Early indicators of prognosis in fulminant hepatic failure [J]. Gastroenterology, 1989,97(2) :439 - 445.
  • 9Yoshiyata T, Hiromitsu K, Masaru S, et al. A multieenter study on the prognosis of fulminant viral hepatitis: Farly prediction for liver transplantation[J]. Hepatology, 1994,19:1065 - 1071.
  • 10Pereira L M,Langley P G,Hayllar K M,et al. Coagulation factor V and ⅥⅡ / V ration as predictors of outcome in paraeetamol induced fulminant hepatic failure: relation to other prognostic indicators [J]. Gut, 1992,33(1) :98 - 102.

共引文献8

同被引文献13

  • 1丛玉隆,魏玉香,张立文,殷宗健,白洁.肝硬化患者凝血、抗凝及纤溶指标的变化与Child-Pugh分级的关系[J].中华肝脏病杂志,2005,13(1):31-34. 被引量:56
  • 2Guo J, Friedman SL. Hepatic fibrogensis[ J ]. Semin Liver Dis,2007, 27(4) :413-426.
  • 3Moreira RK. Hepatic stellate cells and liver fibrosis[J]. Arch Pathol Lab Med ,2007,131 ( 11 ) : 1728-1734.
  • 4Brauer PR. MMPs-role in cardiovascular development and disease [ J ]. Front Biosci ,2006,11 : 447-475.
  • 5Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/uPAR system in human cancers l-J]. Cancer Treatment Reviews, 2008,34 (2) : 122-136.
  • 6Zimmermann HW,Reuken PA,Koeh A,et al. Soluble urokinase plasminogen activator receptor is compart- mentally regulated in decompensated cirrhosis and in- dicates immune activation and short-term mortality [J]. Journal of Internal Medicine, 2013,274 (1): 86- 100.
  • 7Sloand EM, Pfannes L, Scheinberg P, et al. Increased soluble urokinase plasminogen activator receptor (su-PAR) is associated with thrombosis and inhibition of plasmin Generation in paroxysmal nocturnal hemo- globinuria (PNH) patients[J]. Experimental Hema- tology,2008,36(12) : 1616-1624.
  • 8Almasi CE, Hyer-Hansen G, Christensen IJ, et al. Prognostic impact of liberated domain I of the uroki- nase plasminogen activator receptor in squamous cell lung cancer tissue[J]. Lung Cancer, 2005,48 (3) : 349- 355.
  • 9Almasi CE, Hyer-Hansen G, Christensen IJ, et al. Prognostic significance of urokinase plasminogen ac- tivator receptor and its cleaved forms in blood from patients with non-small cell lung cancer[J]. APMIS, 2009,117 (10) : 755-761.
  • 10Stewart CE, Sayers I. Charaeterisation of urokinase plasminogen activator receptor variants in human air- way and peripheral eeUs[J]. BMC Molecular Biology, 2009,10(1) : 75.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部